证券代码：600161 证券简称：天坛生物 公告编号：2026-004 北京天坛生物制品股份有限公司 关于审计机构变更项目质量复核人的公告 本次变更过程中相关工作安排已有序交接，变更事项不会对公司2025年度财务报表审计和2025年末财务 报告内部控制审计工作产生不利影响。 特此公告。 一、本次变更项目质量复核人的情况 天健会计师事务所作为公司2025年度财务报表和2025年末财务报告内部控制审计机构，原委派韦军先生 作为公司2025年度财务报表审计报告和2025年末财务报告内部控制审计报告的项目质量复核人。由于韦 军先生工作安排调整，现委派黄加才先生接替韦军先生作为项目质量复核人。变更后的项目质量复核人 为黄加才先生。 二、新任项目质量复核人的基本情况 黄加才先生2005年7月成为中国注册会计师，自2005年7月开始在天健会计师事务所执业。黄加才先生不 存在违反《中国注册会计师独立性准则第1号一一财务报表审计和审阅业务对独立性的要求》和中国注 册会计师职业道德守则有关独立性要求的情形，最近三年未曾因执业行为受到过刑事处罚、行政处罚、 监督管理措施和纪律处分。 三、本次变更对公司的影响 北京天坛生物制品股份有 ...

证券日报网讯 2月4日，天坛生物发布公告称，近日，公司收到天健会计师事务所（特殊普通合伙） （简称"天健会计师事务所"）《关于变更项目质量复核人的函》。天健会计师事务所作为公司2025年度 财务报表和2025年末财务报告内部控制审计机构，原委派韦军先生作为公司2025年度财务报表审计报告 和2025年末财务报告内部控制审计报告的项目质量复核人。由于韦军先生工作安排调整，现委派黄加才 先生接替韦军先生作为项目质量复核人。变更后的项目质量复核人为黄加才先生。 （文章来源：证券日报） ...

证券代码：600161 证券简称：天坛生物 公告编号：2026-004 一、本次变更项目质量复核人的情况 天健会计师事务所作为公司 2025 年度财务报表和 2025 年末财务报告内部控制审计 机构，原委派韦军先生作为公司 2025 年度财务报表审计报告和 2025 年末财务报告内部 控制审计报告的项目质量复核人。由于韦军先生工作安排调整，现委派黄加才先生接替 韦军先生作为项目质量复核人。变更后的项目质量复核人为黄加才先生。 二、新任项目质量复核人的基本情况 黄加才先生 2005 年 7 月成为中国注册会计师，自 2005 年 7 月开始在天健会计师事 务所执业。黄加才先生不存在违反《中国注册会计师独立性准则第 1 号——财务报表审 计和审阅业务对独立性的要求》和中国注册会计师职业道德守则有关独立性要求的情 形，最近三年未曾因执业行为受到过刑事处罚、行政处罚、监督管理措施和纪律处分。 三、本次变更对公司的影响 本次变更过程中相关工作安排已有序交接，变更事项不会对公司 2025 年度财务报 表审计和 2025 年末财务报告内部控制审计工作产生不利影响。 北京天坛生物制品股份有限公司 关于审计机构变更项目质量复核 ...

证券之星消息，1月29日生物制品板块较上一交易日下跌1.3%，华兰疫苗领跌。当日上证指数报收于 4157.98，上涨0.16%。深证成指报收于14300.08，下跌0.3%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002880 | 卫光生物 | 30.07 | 4.59% | 8.81万 | | 2.66亿 | | 000661 | 长春高新 | 98.30 | 0.92% | 6.47万 | | 6.29亿 | | 300294 | 博雅生物 | 23.15 | 0.92% | 6.32万 | | 1.46亿 | | 300122 | 智飞生物 | 17.99 | 0.73% | - 43.69万 | | 7.78亿 | | 000403 | 派林生物 | 13.86 | 0.51% | 8.83万 | | 1.22亿 | | 600161 | 天坛生物 | 16.79 | 0.42% | 15.16万 | | 2.53亿 | | 6002 ...

Group 1 - The biopharmaceutical sector increased by 0.19% on January 21, with Nearshore Protein leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] - Key stocks in the biopharmaceutical sector showed significant price increases, with Nearshore Protein rising by 6.37% to a closing price of 48.76 [1] Group 2 - The biopharmaceutical sector experienced a net inflow of 77.04 million yuan from institutional investors, while retail investors saw a net outflow of 284 million yuan [2] - Major stocks like Watson Bio and Ganli Pharmaceutical attracted significant institutional investment, with net inflows of 64.45 million yuan and 55.25 million yuan, respectively [3] - Retail investors showed a negative trend in several stocks, with Watson Bio and Ganli Pharmaceutical experiencing net outflows of 33.30 million yuan and 39.14 million yuan, respectively [3]

国药集团旗下天坛生物（600161.SH）近日完成核心人事调整。公司公告显示，因工作调整，原董事长 杨汇川辞去董事长、董事会战略与投资委员会主任委员等职务，仍继续担任第九届董事会董事、总经理 职务。 与此同时，天坛生物召开董事会，选举梁红军出任第九届董事会董事长，并当选为董事会战略与投资委 员会委员、提名委员会委员，同时兼任战略与投资委员会主任委员。 根据公开信息，杨汇川于2022年底接任天坛生物董事长一职，任职期间公司业绩实现稳步增长：2023 年、2024年分别实现营业收入51.8亿元、60.32亿元，同比增幅为21.57%、16.44%；归母净利润分别达 11.1亿元、15.49亿元，同比涨幅为25.99%、39.58%。不过2025年以来，天坛生物出现"增收不增利"的 业绩波动。 有业内人士向21世纪经济报道记者分析，此次人事更替背后，是我国血液制品行业近年业绩分化加剧、 市场竞争持续升级的行业态势。作为行业龙头企业，天坛生物的人事调整或为适应市场变化的战略布 局，国药集团亦有望借此进一步巩固行业地位，在血制行业存量博弈中寻求突破。 角色重构谋破局 此次人事调整中的杨汇川与梁红军，均为深耕国药体系多年 ...

Core Viewpoint - Tian Tan Biological, a subsidiary of China National Pharmaceutical Group, has undergone a significant personnel adjustment with the resignation of Chairman Yang Huichuan and the appointment of Liang Hongjun as the new chairman, indicating a strategic response to the competitive landscape in the blood products industry [1][3][4]. Company Summary - Yang Huichuan, who took over as chairman at the end of 2022, led the company to steady revenue growth, achieving operating revenues of 5.18 billion yuan and 6.032 billion yuan in 2023 and 2024, respectively, with year-on-year growth rates of 21.57% and 16.44% [3]. - The company reported net profits of 1.11 billion yuan and 1.549 billion yuan for the same years, with increases of 25.99% and 39.58% [3]. - However, since 2025, Tian Tan Biological has experienced fluctuations in performance, characterized by "increased revenue without increased profit" [3][5]. Personnel Changes - The new chairman, Liang Hongjun, has extensive experience within the China National Pharmaceutical Group and a strong financial background, which is seen as crucial for addressing the company's current need for cost control and profit stabilization [4][5]. - The dual leadership structure, with Yang remaining as general manager, aims to combine financial oversight with operational expertise [5]. Industry Context - The blood products industry in China has seen increasing performance disparities among companies, with Tian Tan Biological facing intensified competition [3][7]. - The industry has been experiencing a slowdown in growth, with some companies reporting significant revenue declines, while others, including Tian Tan Biological, have shown mixed results [7][8]. - The market is currently characterized by price declines and cash flow pressures, leading to concerns about the sustainability of profits in the short term [8]. Future Outlook - The focus for Tian Tan Biological in 2026 is expected to shift from expansion to improving quality and efficiency, emphasizing cost control and profit stability [6][9]. - The ongoing adjustments in leadership and strategy will be critical for the company to navigate the evolving market dynamics and competitive pressures [9].

Key Points - China Metallurgical Group Corporation (China MCC) expects a decline of over 50% in net profit attributable to shareholders in 2025 due to losses in the real estate sector and increased asset impairment provisions [1] - JAC Motors anticipates a net loss of approximately 1.68 billion yuan in 2025, although this represents a reduction in losses compared to the previous year [2] - Northern Rare Earth forecasts a net profit increase of 116.67% to 134.60% in 2025, driven by improved sales and production efficiency in rare earth products [3] - Shenghong Technology projects a net profit increase of 260.35% to 295% in 2025, attributed to the growing demand for AI infrastructure and high-end products [4] - Lanke Technology expects a net profit increase of 52.29% to 66.46% in 2025, benefiting from strong demand in the AI industry [7] - Aiwai Electronics anticipates a net profit increase of 17.70% to 29.47% in 2025, focusing on high-value chip solutions [25] - Longxin General expects a net profit increase of 47.15% to 60.53% in 2025, driven by steady growth in its core motorcycle and general machinery businesses [28] - China One Heavy Industry predicts a net loss of 310 million to 460 million yuan in 2025, although this represents a significant reduction from the previous year's loss [35] - Kunda Technology expects a net loss of 1.2 billion to 1.5 billion yuan in 2025, impacted by industry supply-demand imbalances [34] - Daqing Energy anticipates a net loss of 1 billion to 1.3 billion yuan in 2025, although this reflects a narrowing of losses compared to the previous year [42]

Core Viewpoint - On January 16, TianTan Biological announced that former chairman Yang Huichuan resigned from multiple positions due to work adjustments, while still retaining his role as a director and general manager of the company [1] Group 1 - Yang Huichuan submitted his resignation from the positions of chairman and chairman of the strategy and investment committee [1] - After resigning from these positions, Yang Huichuan continues to hold 46,800 shares in the company, representing 0.0024% of the total shareholding [1]

证券代码：600161 证券简称：天坛生物 公告编号：2026-002 北京天坛生物制品股份有限公司董事长离任公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京天坛生物制品股份有限公司（以下简称"公司"）董事会收到公司董事 长杨汇川先生递交的书面辞职报告。现将有关情况公告如下： 一、提前离任的基本情况 | 是否继 | 是 | 否 | 存 | 原定 | 离 | 续在上 | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 在 | 未 | 履 | 姓 | 离任 | 任期 | 任 | 市公司 | 具体 | 离任职务 | 行 | 完 | 毕 | | | | | | | | | | | 名 | 时间 | 到期 | 原 | 及其控 | 职务 | 的 | ...